drugset / Trial / NCT03706326
CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer
Phase 1/2
Unknown
20 enrolled
The First Affiliated Hospital of Guangdong Pharmaceutical University
Guangzhou Anjie Biomedical Technology Co., Ltd. · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The study is to assess the safety and efficacy of the immunotherapies using anti-MUC1 CAR T cells and /or PD-1 knockout engineered T cells in the treatment of patients with advanced esophageal cancer.
Timeline
- Start
- 2018-09-28
- Primary completion
- 2021-09-28
- Completion
- 2021-09-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-MUC1 CAR-T cells | Cell therapy | — | — |
| Subject | PD-1 knockout Engineered T cells | Cell therapy | — | — |